Man Group
SNDX icon

Man Group’s Syndax Pharmaceuticals SNDX Stock Holding History

Man Group’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.67M Buy
213,703
+31,687
+17% +$659K 0.01% 1171
2026
Q1 		$4.25M Buy
182,016
+137,378
+308% +$2.99M 0.01% 1235
2025
Q4 		$938K Sell
44,638
-130,313
-74% -$2.27M ﹤0.01% 1691
2025
Q3 		$2.69M Sell
174,951
-53,216
-23% -$697K ﹤0.01% 1300
2025
Q2 		$2.14M Buy
228,167
+94,031
+70% +$1.03M ﹤0.01% 1387
2025
Q1 		$1.65M Buy
134,136
+12,597
+10% +$178K ﹤0.01% 1432
2024
Q4 		$1.61M Buy
+121,539
New +$2.08M ﹤0.01% 1377

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Man Group's SNDX Position: Q2 2026 in Review

Man Group increased its Syndax Pharmaceuticals (SNDX) stake by 17% in Q2 2026, buying an estimated $659K and bringing the position to 213,703 shares worth $4.67M. The position accounts for 0.01% of the portfolio, ranked #1171.

Man Group first reported a position in SNDX in Q4 2024 and has held it in 7 quarters since. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Man Group held 213,703 shares of Syndax Pharmaceuticals worth $4.67M as of Q2 2026.
  • Man Group bought 31,687 Syndax Pharmaceuticals shares in Q2 2026, an estimated $659K.
  • Syndax Pharmaceuticals made up 0.01% of Man Group's portfolio in Q2 2026, its #1171 holding.
  • Man Group first reported a position in Syndax Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.